Castle Biosciences shared new performance data from a novel, multi-center, independent cohort demonstrating how the independent risk-stratification of DecisionDx-SCC can significantly improve metastatic risk predictions by complementing current staging systems. Additionally, consistent with previous studies,3,4 DecisionDx-SCC independently and significantly stratified a novel cohort according to patients’ biologic metastatic risk. This study analyzed the performance of the DecisionDx-SCC test in a novel, independent performance cohort of 534 patients with primary cSCC and one or more risk factors from 45 contributing centers. The data from the study consistently demonstrated the performance of DecisionDx-SCC to classify risk for metastasis in cSCC patients with one or more risk factors. Multivariate models showed that the metastatic risk prediction of AJCC8 and BWH staging systems were significantly improved when DecisionDx-SCC test results were included. Overall, the study data further support that DecisionDx-SCC independently predicts metastatic risk for patients with cSCC and can complement clinicopathologic staging systems and improve risk predictions based on staging alone to support risk-aligned patient management decisions.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CSTL: